Peptides News and Research

RSS

Discovery Laboratories reports net loss of $11.3 million for third quarter 2014

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the third quarter ended September 30, 2014, as well as recent business updates.

6 Nov 2014

CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

CARLINA Technologies, a biotechnology company specialized in the development of nanomedicines, today announces the signing of a collaborative agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in bone and cartilage repair. Financial details were not disclosed.

5 Nov 2014

Scientists develop new system to treat a host of genetic conditions

As potential next-generation therapeutics and research tools, few life sciences technologies hold more promise than genome-editing proteins – molecules that can be programmed to alter specific genes in order to treat or even cure genetic diseases.

31 Oct 2014

Study opens door to new treatments for brain diseases

Delivering life-saving drugs across the blood-brain barrier (BBB) might become a little easier thanks to a new report published in the November 2014 issue of The FASEB Journal.

31 Oct 2014

Novel 'designer' nanodevice could improve cancer diagnostics, treatment

Cancer diagnostics and treatment options could be drastically improved with the creation of a 'designer' nanodevice being developed by researchers from the UK, Italy, the US and Argentina.

22 Oct 2014

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

GEP-NETs stands for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). This is a type of rare cancer that is increasing in incidence and prevalence – more on this later.

22 Oct 2014

YEDA and XL-protein sign deal to commercialize PASylated IFN superagonis

YEDA Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist -- PAS-YNSα8 -- which has been jointly developed by scientists at the Weizmann Institute and XL-protein.

21 Oct 2014

Research findings point toward new therapeutic target for aggressive breast cancer

One of the first-known oncogenes has a protein partner that helps breast cancer proliferate and when it's blocked, so is the cancer, scientists report.

15 Oct 2014

Imperial researchers plan to test DTP3 drug in multiple myeloma patients

Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year.

14 Oct 2014

BIDMC scientists uncover new class of molecules that protects against diabetes

Scientists at the Salk Institute and Beth Israel Deaconess Medical Center in Boston have discovered a new class of molecules—produced in human and mouse fat—that protects against diabetes.

10 Oct 2014

TSRI research points toward new method for treating atherosclerosis

Scientists at The Scripps Research Institute have created a synthetic molecule that mimics "good" cholesterol and have shown it can reduce plaque buildup in the arteries of animal models. The molecule, taken orally, improved cholesterol in just two weeks.

10 Oct 2014

Discovery offers promising new avenue for prevention, treatment of type 2 diabetes

The surprising discovery of a previously unidentified class of lipid molecules that enhance insulin sensitivity and blood sugar control offers a promising new avenue for the prevention and treatment of type 2 diabetes.

10 Oct 2014

Researchers are developing compounds to combat causative agents of periodontitis

A total 12 million Germans suffer from periodontitis. If the inflammation remains untreated, this could lead to tooth loss. However, it is also suspected of triggering many other diseases, like cardiopulmonary diseases. Researchers are studying the interactions, and developing compounds to combat the causative agents.

9 Oct 2014

Researchers generate fruit fly model, unveil key genetic factors behind human colon cancer

Researchers at the Institute for Research in Biomedicine (IRB Barcelona) have managed to generate a fruit fly (Drosophila melanogaster) model that reproduces human colon cancer. With two publications appearing in PLoS One and EMBO Reports, the IRB team also unveil the function of a key gene in the development of the disease.

9 Oct 2014

New drug discovery tool against Ebola virus

University of Utah biochemists have reported a new drug discovery tool against the Ebola virus. According to a study published in this week's online edition of Protein Science, they have produced a molecule, known as a peptide mimic, that displays a functionally critical region of the virus that is universally conserved in all known species of Ebola.

8 Oct 2014

First three recipients of inaugural Harry Winston Fellowships named

Harry Winston, Inc. and the UCLA Children's Discovery and Innovation Institute have named the first three recipients of the inaugural Harry Winston Fellowships.

7 Oct 2014

Weekly growth hormone on course for phase III in children

A long-lasting formulation of human growth hormone appears to be as effective as standard daily treatment in paediatric patients with growth hormone deficiency, researchers reported at the European Society of Paediatric Endocrinology annual meeting in Dublin, Ireland.

2 Oct 2014

Empirical sulphonylurea therapy an option for neonatal diabetes

A report of empirical sulphonylurea therapy in neonatal diabetes prior to genetic diagnosis highlights contrasting approaches to the problem.

2 Oct 2014

Ohio State researchers develop novel anticancer peptide vaccines and inhibitors

Researchers have developed two new anticancer peptide vaccines and two peptide inhibitors as part of a larger peptide immunotherapy effort at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

25 Sep 2014

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Antisense Therapeutics is pleased to report the publication of previously generated Phase IIa clinical trial data on ATL1102 in the medical journal Neurology.

22 Sep 2014